43 completed. 43 Phase 2, 8 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 43 |
| Phase 1 | 8 | Completed 8 |
| Phase 3 | 1 | Completed 1 |
Follow Fibrosarcoma: new trials by email Literature Review of Fibrosarcoma trials Research Report on Fibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Selumetinib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 21 | 2019-10-02 | 2026-05-27 |
| APX005M and Doxorubicin in Advanced Sarcoma Doxorubicin, APX005M - Soft Tissue Sarcoma | Phase 2 | Completed | Alexander Z. Wei, MD | 27 | 2019-03-20 | 2026-06-10 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study - Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor | Phase 2 | Completed | Children's Oncology Group | 62 | 2015-10-12 | 2022-01-13 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) ganetespib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma | Phase 1 / Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 20 | 2013-12-01 | 2019-05-15 |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors everolimus, bevacizumab - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 25 | 2012-09-01 | 2019-03-06 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2012-08-22 | 2017-11-30 |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2012-06-18 | 2018-12-11 |
| Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 2 | Completed | OHSU Knight Cancer Institute | 54 | 2012-03-13 | 2021-09-27 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma temsirolimus plus liposomal doxorubicin - Sarcoma | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2009-09-01 | 2019-03-11 |
| Sorafenib and Dacarbazine in Soft Tissue Sarcoma Sorafenib and Dacarbazine - Sarcoma, Synovial Sarcoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 37 | 2009-02-01 | 2015-11-20 |
| AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2008-02-01 | 2018-06-29 |
| BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors BI 2536, high performance liquid chromatography, mass spectrometry - Breast Cancer, Endometrial Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 76 | 2007-07-01 | 2013-10-07 |
| Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung REOLYSIN® - Osteosarcoma, Ewing Sarcoma Family Tumors | Phase 2 | Completed | Oncolytics Biotech | 53 | 2007-06-01 | 2014-10-02 |
| Trial of Dasatinib in Advanced Sarcomas Dasatinib - Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 366 | 2007-05-01 | 2018-11-23 |
| Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas sunitinib malate - Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 53 | 2007-04-01 | 2016-01-20 |
Showing 20 of 43. Sign in to see all of them.
Sarcoma (35) · Neurofibrosarcoma (25) · Leiomyosarcoma (23) · Liposarcoma (23) · Histiocytoma, Malignant Fibrous (21) · Sarcoma, Synovial (21) · Hemangiosarcoma (17) · Rhabdomyosarcoma (17) · Dermatofibrosarcoma (13) · Sarcoma, Alveolar Soft Part (10) · Hemangiopericytoma, Malignant (9) · Osteosarcoma (9) · Malignant mesenchymal tumor (8) · Chondrosarcoma (7)
Neoplasms by Histologic Type (43) · Neoplasms, Connective Tissue (43) · Neoplasms, Connective and Soft Tissue (43) · Neoplasms, Fibrous Tissue (43) · Neoplasms (41) · Neoplasms, Nerve Tissue (30) · Neoplasms, Muscle Tissue (27) · Nervous System Diseases (26) · Nervous System Neoplasms (26) · Neurofibroma (25) · Neuromuscular Diseases (25) · Peripheral Nervous System Diseases (25) · Peripheral Nervous System Neoplasms (25) · Nerve Sheath Neoplasms (24) · Neoplasms, Adipose Tissue (23)
Imatinib Mesylate (8) · Doxorubicin (5) · Radiotherapy (4) · Filgrastim (3) · Ifosfamide (3) · Sirolimus (3) · Bevacizumab (2) · Carboplatin (2) · Etoposide (2) · Sorafenib (2) · Sunitinib (2) · pazopanib (2) · temsirolimus (2) · 130-nm albumin-bound paclitaxel (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)
National Cancer Institute (NCI) (9) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Sarcoma Alliance for Research through Collaboration (6) · Memorial Sloan Kettering Cancer Center (3) · Novartis Pharmaceuticals (2) · Alexander Z. Wei, MD (1) · BioAtla, Inc. (1) · Celgene (1) · Children's Oncology Group (1) · Daiichi Sankyo (1) · Dermatologic Cooperative Oncology Group (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Massachusetts General Hospital (1) · NCIC Clinical Trials Group (1) · NYU Langone Health (1)
United States (31) · Belgium (5) · Canada (5) · France (5) · United Kingdom (5) · Germany (3) · Netherlands (3) · Denmark (2) · Puerto Rico (2) · Australia (1) · Hong Kong (1) · Ireland (1) · Italy (1) · Slovakia (1) · Spain (1)
AeRang Kim, MD, PhD (2) · Brigitte C. Widemann, MD (2) · Brigitte Widemann, MD (2) · Scott Schuetze, MD, PhD (2) · Aaron R Weiss (1) · Alberto Chiappori, M.D. (1) · Alexander Wei, MD (1) · Allan T. van Oosterom, MD, PhD (1) · Annabel B.M. Foot (1) · Axel Le Cesne, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Brian H. Kushner, MD (1) · Christophe Bergeron (1) · Christopher W Ryan (1) · David M Loeb, MD, PhD (1)
PMID 19451433, PMID 31401903, PMID 32827353, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 19088049, PMID 19451429, PMID 20338746, PMID 20471824, PMID 20932656, PMID 23382028, PMID 27502708, PMID 30410720, PMID 32089640, PMID 32554315, PMID 32702309, PMID 34515544, PMID 37523624, PMID 38579194
P30CA008748 (3), N01CM62206 (2), U10CA032102 (2), U10CA098543 (2), U10CA180886 (2), N01CM62201 (1), N01CM62203 (1), P30CA012197 (1), P30CA016087 (1), R21CA117128 (1), U01CA069856 (1), U10CA031946 (1), U10CA081851 (1), U10CA180821 (1), U10CA180830 (1)